Added to YB: 2024-02-14
Pitch date: 2024-02-13
RENB [bearish]
Renovaro Inc.
+94.6%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
Market Cap
$54.8M
Pitch Price
$19.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.58
P/E
-0.38
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
[SHORT] Renovaro BioSciences: A Worthless AI Shell Game With A Murderous Magician Past
$RENB (prev ENOC) embroiled in controversy: dubious practices, ill-fated AI pivot. Founder awaits trial for murder-for-hire & academic fraud. Insiders capitalize on suspect merger hype. Undisclosed SEC probe, lawsuits loom as trials rest on discredited science. Grim outlook for shares.
Read full article (29 min)